Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sol-Gel Technologies's annualized net income for the quarter that ended in Mar. 2026 was $-14.91 Mil. Sol-Gel Technologies's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $37.11 Mil. Therefore, Sol-Gel Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -40.17%.
The historical rank and industry rank for Sol-Gel Technologies's Return-on-Tangible-Equity or its related term are showing as below:
SLGL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -574.54 Med: -36.82 Max: 6.05
Current: -3.43
During the past 11 years, Sol-Gel Technologies's highest Return-on-Tangible-Equity was 6.05%. The lowest was -574.54%. And the median was -36.82%.
SLGL's Return-on-Tangible-Equity is ranked better than 74.71% of 1202
companies
in the Biotechnology industry
Industry Median: -42.435
vs SLGL: -3.43
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sol-Gel Technologies Return-on-Tangible-Equity Related Terms
Sol-Gel Technologies Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sol-Gel Technologies's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLGL vs ALEC, LENZ, CNXU: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Sol-Gel Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -40.17% mean?
Sol-Gel Technologies (SLGL) has a Return-on-Tangible-Equity of -40.17% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sol-Gel Technologies and its competitors. According to the industry distribution chart, Sol-Gel Technologies ranks #304 out of 1202 companies in the Biotechnology industry, placing it in the top 25.3%.
Is Sol-Gel Technologies' Return-on-Tangible-Equity too high?
Sol-Gel Technologies' current Return-on-Tangible-Equity is -40.17%. Based on the distribution chart, Sol-Gel Technologies ranks #304 out of 1202 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sol-Gel Technologies has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Return-on-Tangible-Equity compare to ALEC and LENZ?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #304 out of 1202 companies for Return-on-Tangible-Equity. This puts Sol-Gel Technologies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sol-Gel Technologies and its competitors. Sol-Gel Technologies's current Return-on-Tangible-Equity is -40.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $65.37, compared to a current price of $74.40 — trading 13.8% above its estimated fair value. The current Return-on-Tangible-Equity is -40.17%. Sol-Gel Technologies' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Return-on-Tangible-Equity is -40.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (SLGL) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of $74.40 is trading 13.8% above its estimated GF Value™ of $65.37.
GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.
Key valuation signals for SLGL:
Return-on-Tangible-Equity: -40.17%
GF Value™: $65.37 vs. price of $74.40 (13.8% above fair value)
No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
55GF Score
Get the complete analysis for SLGL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLGL has been successfully added to your 
